Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 19.4% during mid-day trading on Wednesday . The stock traded as low as C$0.14 and last traded at C$0.15. 519,694 shares changed hands during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The firm has a fifty day simple moving average of C$0.19 and a 200 day simple moving average of C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The stock has a market cap of C$21.13 million, a price-to-earnings ratio of -4.23 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Learn Technical Analysis Skills to Master the Stock Market
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- Insider Trades May Not Tell You What You Think
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
